{"schema_version":"secwatch.filing_event.v1","accession":"0001326190-24-000047","form_type":"8-K","ticker":"ALT","cik":"0001326190","company_name":"Altimmune, Inc.","filed_at":"2024-11-12T23:59:59+00:00","discovered_at":"2026-05-14T18:03:08.115936+00:00","generated_at":"2026-05-30T01:38:10.697157+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Altimmune Q3 net loss $22.8M; IMPACT enrollment done, FDA obesity plan set","bullets":["Net loss of $22.8M ($0.32/share) vs $20.7M ($0.39/share) in Q3 2023.","Cash, equivalents and short-term investments total $139.4M as of Sept 30, 2024.","Completed enrollment in Phase 2b IMPACT trial for MASH; top-line data expected Q2 2025.","FDA agreed on Phase 3 obesity program design; IND submissions for up to three additional indications planned.","Appointed Greg Weaver as CFO on November 11, 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001326190-24-000047","json":"https://secwatch.observer/filing/0001326190-24-000047.json","markdown":"https://secwatch.observer/filing/0001326190-24-000047.md","text":"https://secwatch.observer/filing/0001326190-24-000047.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1326190/000132619024000047/0001326190-24-000047-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1326190/000132619024000047/alt-20241112x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T01:38:10.697157+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}